ストックスクリーナーアプリを入手
0.00
100.00%
-17.03
アフターアワーズ：
17.04
17.04
+
Theravance Biopharma Inc (TBPH) 最新ニュース
Theravance Biopharma (TBPH) shares were canceled on September 23 after its Zymeworks merger. - Stock Titan
Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media
Form 4 Theravance Biopharma For: 24 September By Investing.com - Investing.com Canada
Zymeworks now owns Theravance Biopharma (TBPH). A director's shares were canceled for cash and milestone rights. - Stock Titan
A director's shares became rights to $17 each plus a contingent payment in Theravance Biopharma's (TBPH) merger. - Stock Titan
A 150,000-share insider option was cancelled without payment in Theravance Biopharma (TBPH)'s merger. - Stock Titan
Vancouver biotech Zymeworks closes US$929M Theravance deal - biv.com
Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com
TBPH Suspended by BTIGAnalyst Rating Remains Neutral - GuruFocus
Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media
Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones - Stock Traders Daily
Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Australia
Theravance Biopharma CEO Rick E Winningham resigns; Kristin Stafford, Scott Platshon and Paul Schneider named directors - TradingView
Theravance Biopharma (Nasdaq: TBPH) is named in a notice to remove its shares from Nasdaq. - Stock Titan
Zymeworks completes acquisition of Theravance Biopharma - Investing.com
Theravance Biopharma, Inc. Announces Resignation of Rick E Winningham from Chief Executive Officer, Effective September 23, 2026 - marketscreener.com
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from NASDAQ Biotechnology Index - marketscreener.com
Theravance Biopharma issues disclosures amid Zymeworks merger - TipRanks
Form 8K Theravance Biopharma Inc For: 18 September By Investing.com - Investing.com Nigeria
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - Kalkine Media
Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com Nigeria
Theravance Biopharma SVP Farnum Rhonda Sells 13,314 Shares at $17.03 Each - Kalkine Media
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Navigating the Biotech Seas with Strategic Collaborations - DirectorsTalk Interviews
Theravance Biopharma (TBPH) Insider Sale: SVP, COMM & MEDICAL AF - GuruFocus
Theravance Biopharma SVP Rhonda Farnum sells $226k in stock - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $226k in stock By Investing.com - Investing.com South Africa
Pre-arranged stock sale at Theravance Biopharma (TBPH) - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) officer plans $226,793 stock sale - Stock Titan
Price-Driven Insight from (TBPH) for Rule-Based Strategy - Stock Traders Daily
Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates - kalkine.com.au
Form 8K Theravance Biopharma Inc For: 10 September By Investing.com - Investing.com South Africa
Theravance Bi in merger with Zymeworks faces shareholder suits, supplements proxy with disclosures - TradingView
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Theravance Biopharma Inc. (TBPH) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Theravance Biopharma Inc. (TBPH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial - TradingView
Theravance Biopharma (NASDAQ:TBPH): What Could Its Scheduled Update Reveal? - Kalkine Media
FDA says Theravance (TBPH) needs more data on nOH drug trial - Stock Titan
Theravance (TBPH) Q1 2026 Scorecard: EPS Beats Its Estimate in the Current Update; Closing Move: The Stock Records a Flat ReactionForward EPS Estimate - vinanet.vn
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Madison Avenue Partners, LP Trims Theravance Biopharma Inc (TBPH) Stake in Portfolio Rebalancing Move - GuruFocus
Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH - TradingView
Theravance (TBPH) Update: Rises 0.18% to $16.98 on the Day; Price Setup: Traders Can Monitor the $16.13-$17.83 RangeSupport Level Bounce - vinanet.vn
Theravance Biopharma (TBPH) Edges Higher to $16.97, Trapped Between Key Support and ResistanceFactor Valuation - vinanet.vn
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):